Janus kinase (JAK) inhibitors are becoming an increasingly prominent class of drug in the treatment of myeloproliferative neoplasms (MPNs), in... The post Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs appeared first on VJHemOnc.